| 产品描述: | NU1025 (NSC 696807)是一种有效的 PARP 抑制剂,IC50 为 400 nM |
| 靶点: |
PARP:400 nM;PARP |
| 体外研究: |
NU1025(0.2 mM)处理可减轻H2O2诱导的细胞毒性。NU1025本身对细胞活性无影响。在SIN-1(0.8 mM)处理后的细胞中,NU1025预处理能显著增加细胞存活率(82.59±4.67%)。NU1025在D54和U251细胞中没有可检测的促增殖作用。NU1025可显著抑制TPT和RT对PARP-1活性的促进作用。200 μM NU1025单独处理后,没有检测出DNA链断裂 |
| 体内研究: |
大鼠经NU1025(1和3 mg/kg)处理后,与溶剂组相比可分别减少25%和45%梗死。NU1025(1和3 mg/kg)处理可显著降低水肿体积。NU1025可显著改善神经功能损伤 |
| 细胞实验: |
Cell lines: D54和U251细胞 Concentrations: 160 μM Incubation Time: 5 天 Method: 以2,500个细胞/孔的密度接种细胞至96孔板中,用指示剂量的NU1025处理。培养基中的贴壁细胞经250 kVp X-射线(剂量率0.5 Gy/min)处理。以未经处理的细胞为对照。孵育5天后,MTT法检测细胞增殖率 |
| 动物实验: |
Animal Models: 雄性Sprague-Dawley大鼠 Dosages: 3 mg/kg Administration: 腹腔注射 |
| 参考文献: |
1. McCabe N, et al. BRCA2-deficient CAPAN-1 cells are extremely sensitive to the inhibition of Poly (ADP-Ribose) polymerase: an issue of potency. Cancer Biol Ther. 2005, 4(9), 934-936. 2. Kaundal RK, et al. Neuroprotective effects of NU1025, a PARP inhibitor in cerebral ischemia are mediated through reduction in NAD depletion and DNA fragmentation. Life Sci. 2006, 79(24), 2293-2302. 3. Sabbatino F, et al. Effect of p53 activity on the sensitivity of human glioblastoma cells to PARP-1 inhibitor in combination with topoisomerase I inhibitor or radiation. Cytometry A. 2014, 85(11), 953-961. 4. Bowman KJ, et al. Differential effects of the poly (ADP-ribose) polymerase (PARP) inhibitor NU1025 on topoisomerase I and II inhibitor cytotoxicity in L1210 cells in vitro. Br J Cancer. 2001, 84(1), 106-112. |
| 溶解性: |
Soluble in DMSO |
| 保存条件: |
-20℃ |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
5.676 ml |
28.382 ml |
56.763 ml |
| 5 mM |
1.135 ml |
5.676 ml |
11.353 ml |
| 10 mM |
0.568 ml |
2.838 ml |
5.676 ml |
| 50 mM |
0.114 ml |
0.568 ml |
1.135 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |